Improved glioblastoma treatment with Ad5/35 fiber chimeric conditionally replicating adenoviruses

Journal of Gene Medicine

Volumn 9, Issue 9, 2007, Pages 764-778

  Hoffman, Dennis ^a   Meyer, Bernhard ^b,c   Wildner, Oliver ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Conditionally replicative adenoviruses vectors; Fiber chimeric Ad5 35; Glioblastoma multiforme

Indexed keywords

ADENOVIRUS VECTOR; ARGINYLGLYCYLASPARTIC ACID; CYCLOOXYGENASE 2; FIREFLY LUCIFERASE; GLIAL FIBRILLARY ACIDIC PROTEIN; INTEGRIN; KI 67 ANTIGEN; ONCOLYTIC ADENOVIRUS; TRANSCRIPTION FACTOR E2F1; VIRUS PROTEIN; VIRUS RECEPTOR;

ADENOVIRUS 5; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL SPECIFICITY; CHIMERA; CONTROLLED STUDY; FEMALE; GENE DELETION; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSDUCTION; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; SURVIVAL TIME; TUMOR MODEL; TUMOR XENOGRAFT; VIRAL GENE THERAPY; VIRUS REPLICATION; WILD TYPE;

ADENOVIRIDAE; ADENOVIRUS E1A PROTEINS; ADENOVIRUS E4 PROTEINS; ANIMALS; CELL LINE, TUMOR; CYTOPATHOGENIC EFFECT, VIRAL; FEMALE; GENE THERAPY; GLIOBLASTOMA; HUMANS; LUCIFERASES; MICE; MICE, INBRED BALB C; ONCOLYTIC VIRUSES; ORGAN SPECIFICITY; PROMOTER REGIONS (GENETICS); TRANSCRIPTION, GENETIC; TRANSDUCTION, GENETIC; VIRAL PROTEINS; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ADENOVIRIDAE; ANIMALIA; HUMAN ADENOVIRUS TYPE 5;

EID: 34548565837     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1076     Document Type: Article

References (86)

1. Castro MG, Cowen R, Williamson IK, et al. Current and future strategies for the treatment of malignant brain tumors. Pharmacol Ther 2003; 98: 71-108.
2. Germano IM, Fable J, Gultekin SH, et al. Adenovirus/herpes simplex-thymidine kinase/ganciclovir complex: preliminary results of a phase I trial in patients with recurrent malignant gliomas. J Neurooncol 2003; 65: 279-289.
3. Lang FF, Bruner JM, Fuller GN, et al. Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J Clin Oncol 2003; 21: 2508-2518.
4. Immonen A, Vapalahti M, Tyynela K, et al. AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study. Mol Ther 2004; 10:967-972.
5. Chiocca EA, Abbed KM, Tatter S, et al. A phase I open-label, dose-escalation, multi-institutional trial of injection with an ElB-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Mol Ther 2004; 10: 958-966.
6. Lamfers ML, Grill J, Dirven CM, et al. Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. Cancer Res 2002; 62: 5736-5742.
7. Ulasov IV, Tyler MA, Zheng S, et al. CD46 represents a target for adenoviral gene therapy of malignant glioma. Hum Gene Ther 2006; 17: 556-564.
8. Bergelson JM, Cunningham JA, Droguett G, et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997; 275: 1320-1323.
9. Tomoko RP, Xu R, Philipson L. HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc Natl Acad Sci U S A 1997; 94: 3352-3356.
10. Wickham TJ, Mathias P, Cheresh DA, et al. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 1993; 73: 309-319.
11. Meier O, Greber UF. Adenovirus endocytosis. J Gene Med 2004; 6(Suppl 1): S152-S163.
12. Roelvink PW, Lizonova A, Lee JG, et al. The coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F. J Virol 1998; 72: 7909-7915.
13. Sirena D, Lilienfeld B, Eisenhut M, et al. The human membrane cofactor CD46 is a receptor for species B adenovirus serotype 3. J Virol 2004; 78: 4454-4462.
14. Gaggar A, Shayakhmetov DM, Lieber A. CD46 is a cellular receptor for group B adenoviruses. Nat Med 2003; 9: 1408-1412.
15. Segerman A, Atkinson JP, Marttila M, et al. Adenovirus type 11 uses CD46 as a cellular receptor. J Virol 2003; 77: 9183-9191.
16. Marttila M, Persson D, Gustafsson D, et al. CD46 is a cellular receptor for all species B adenoviruses except types 3 and 7. J Virol 2005; 79: 14429-14436.
17. Segerman A, Arnberg N, Erikson A, et al. There are two different species B adenovirus receptors: sBAR, common to species B1 and B2 adenoviruses, and sB2AR, exclusively used by species B2 adenoviruses. J Virol 2003; 77: 1157-1162.
18. Wu E, Trauger SA, Pache L, et al. Membrane cofactor protein is a receptor for adenoviruses associated with epidemic keratoconjunctivitis. J Virol 2004; 78: 3897-3905.
19. Lemckert AA, Grimbergen J, Smits S, et al. Generation of a novel replication-incompetent adenoviral vector derived from human adenovirus type 49: manufacture on PER.C6 cells, tropism and immunogenicity. J Gen Virol 2006; 87: 2891-2899.
20. Short JJ, Pereboev AV, Kawakami Y, et al. Adenovirus serotype 3 utilizes CD80 (B7.1) and CD86 (B7.2) as cellular attachment receptors. Virology 2004; 322: 349-359.
21. Wildner O. Comparison of replication-selective, oncolytic viruses for the treatment of human cancers. Curr Opin Mol Therapeut 2003; 5: 351-361.
22. Alemany R, Balague C, Curiel DT. Replicative adenoviruses for cancer therapy. Nat Biotechnol 2000; 18: 723-727.
23. Rodriguez R, Schuur ER, Lim HY, et al. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res 1997; 57: 2559-2563.
24. Parr MJ, Manome Y, Tanaka T, et al. Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector. Nat Med 1997; 3: 1145-1149.
25. Hallenbeck PL, Chang YN, Hay C, et al. A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. Hum Gene Ther 1999; 10: 1721-1733.
26. Kurihara T, Brough DE, Kovesdi I, et al. Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. J Clin Invest 2000; 106: 763-771.
27. Kohno S, Nakagawa K, Hamada K, et al. Midkine promoter-based conditionally replicative adenovirus for malignant glioma therapy. Oncol Rep 2004; 12: 73-78.
28. Van Houdt WJ, Haviv YS, Lu B, et al. The human survivin promoter: a novel transcriptional targeting strategy for treatment of glioma. J Neurosurg 2006; 104: 583-592.
29. Ito H, Aoki H, Kuhnel F, et al. Autophagic cell death of malignant glioma cells induced by a conditionally replicating adenovirus. J Natl Cancer Inst 2006; 98: 625-636.
30. Hitt MM, Graham FL. Adenovirus ElA under the control of heterologous promoters: wide variation in E1A expression levels has little effect on virus replication. Virology 1990; 179: 667-678.
31. Fuerer C, Iggo R. Adenoviruses with Tcf binding sites in multiple early promoters show enhanced selectivity for tumour cells with constitutive activation of the wnt signalling pathway. Gene Ther 2002; 9:270-281.
32. Hernandez-Alcoceba R, Pihalja M, Qian D, et al. New oncolytic adenoviruses with hypoxia- and estrogen receptor-regulated replication. Hum Gene Ther 2002; 13: 1737-1750.
33. Johnson L, Shen A, Boyle L, et al. Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents. Cancer Cell 2002; 1: 325-337.
34. Banerjee NS, Rivera AA, Wang M. et al. Analyses of melanoma-targeted oncolytic adenoviruses with tyrosinase enhancer/ promoter-driven ElA, E4, or both in submerged cells and organotypic cultures. Mol Cancer Ther 2004; 3: 437-449.
35. Li X, Zhang YP, Kim HS, et al. Gene therapy for prostate cancer by controlling adenovirus El a and E4 gene expression with PSES enhancer. Cancer Res 2005; 65: 1941-1951.
36. Hoffmann D, Wildner O. Restriction of adenoviral replication to the transcriptional intersection of two different promoters for colorectal and pancreatic cancer treatment. Mol Cancer Ther 2006; 5: 1-8.
37. Barker DD, Berk AJ. Adenovirus proteins from both ElB reading frames are required for transformation of rodent cells by viral infection and DNA transfection. Virology 1987; 156: 107-121.
38. Hall AR, Dix BR, O'Carroll SJ, et al. p53-dependent cell death/ apoptosis is required for a productive adenovirus infection. Nat Med 1998; 4: 1068-1072.
39. Rothmann T, Hengstermann A, Whitaker NJ, et al. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J Virol 1998; 72: 9470-9478.
40. Goodrum FD, Ornelles DA. p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lyric infection. J Virol 1998; 72: 9479-9490.
41. Goldsmith KT, Dion LD, Curiel DT, et al. trans El component requirements for maximal replication of El-defective recombinant adenovirus. Virology 1998; 248: 406-419.
42. Turnell AS, Grand RJ, Gallimore PH. The replicative capacities of large ElB-null group A and group C adenoviruses are independent of host cell p53 status. J Virol 1999; 73: 2074-2083.
43. Harada JN, Berk AJ. p53-Independent and -dependent requirements for ElB-55K in adenovirus type 5 replication. J Virol 1999; 73: 5333-5344.
44. Hay JG, Shapiro N, Sauthoff H, et al. Targeting the replication of adenoviral gene therapy vectors to lung cancer cells: the importance of the adenoviral Elb-55kD gene. Hum Gene Ther 1999; 10: 579-590.
45. Vollmer CM, Ribas A, Butterfield LH, et al. p53 selective and nonselective replication of an E1B-deleted adenovirus in hepatocellular carcinoma. Cancer Res 1999; 59: 4369-4374.
46. Wildner O, Morris JC. The role of the E1B 55 kDa gene in oncolytic adenoviral vectors expressing HSV-tk: assessment of anti-tumor efficacy and toxicity. Cancer Res 2000; 60: 4167-4174.
47. Morris JC, Wildner O. Therapy of head and neck squamous cell carcinoma with an oncolytic adenovirus expressing HSV-tk. Mol Ther 2000; 1: 56-62.
48. Wildner O, Morris JC. Therapy of peritoneal carcinomatosis from colon cancer with oncolytic adenoviruses. J Gene Med 2000; 2:353-360.
49. Fueyo J, Gomez-Manzano C, Alemany R, et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 2000; 19: 2-12.
50. Asaoka K, Tada M, Sawamura Y, et al. Dependence of efficient adenoviral gene delivery in malignant glioma cells on the expression levels of the coxsackievirus and adenovirus receptor. J Neurosurg 2000; 92: 1002-1008.
51. Fuxe J, Liu L, Malin S, et al. Expression of the coxsackie and adenovirus receptor in human astrocytic tumors and xenografts. Int J Cancer 2003; 103: 723-729.
52. Dmitriev I, Krasnykh V, Miller CR, et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 1998; 72: 9706-9713.
53. Brouwer E, Havenga MJ, Ophorst O, et al. Human adenovirus type 35 vector for gene therapy of brain cancer: improved transduction and bypass of pre-existing anti-vector immunity in cancer patients. Cancer Gene Ther 2007; 14: 211-219.
54. Mattern RH, Read SB, Pierschbacher MD, et al. Glioma cell integrin expression and their interactions with integrin antagonists: Research Article. Cancer Ther 2005; 3A: 325-340.
55. Steinstraesser L, Tippler B, Mertens J, et al. Inhibition of early steps in the lentiviral replication cycle by cathelicidin host defense peptides. Retrovirology 2005; 2: 2.
56. Besnard F, Brenner M, Nakatani Y, et al. Multiple interacting sites regulate astrocyte-specific transcription of the human gene for glial fibrillary acidic protein. J Biol Chem 1991; 266: 18877-18883.
57. Myers RL, Ray SK, Eldridge R, et al. Functional characterization of the brain-specific FGF-1 promoter, FGF-1.B. J Biol Chem 1995; 270: 8257-8266.
58. Kurihara H, Zama A, Tamura M, et al. Glioma/glioblastoma-specific adenoviral gene expression using the nestin gene regulator. Gene Ther 2000; 7: 686-693.
59. Wei Q, Miskimins WK, Miskimins R. The Sp1 family of transcription factors is involved in p27 (Kip1)-mediated activation of myelin basic protein gene expression. Mol Cell Biol 2003; 23: 4035-4045.
60. Inoue H, Tanabe T, Umesono K. Feedback control of cyclooxygenase-2 expression through PPARgamma. J Biol Chem 2000; 275: 28028-28032.
61. Wadler S, Yu B, Tan JY, et al. Persistent replication of the modified chimeric adenovirus ONYX-015 in both tumor and stromal cells from a patient with gall bladder carcinoma implants. Clin Cancer Res 2003; 9: 33-43.
62. Hoffmann D, Jogler C, Wildner O. Effects of the Ad5 upstream El region and gene products on heterologous promoters. J Gene Med 2005; 7: 1356-1366.
63. Kim SY, Woo MS, Kim WK, et al. Glial cell-specific regulation of the JC virus early promoter by histone deacetylase inhibitors. J Virol 2003; 77: 3394-3401.
64. Horikawa I, Cable PL, Afshari C, et al. Cloning and characterization of the promoter region of human telomerase reverse transcriptase gene. Cancer Res 1999; 59: 826-830.
65. Maity A, Pore N, Lee J, et al. Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3′-kinase and distinct from that induced by hypoxia. Cancer Res 2000; 60: 5879-5886.
66. Hoffmann D, Wildner O. Efficient generation of double heterologous promoter controlled oncolytic adenovirus vectors by a single homologous recombination step in Escherichia coli. BMC Biotechnol 2006; 6: 36.
67. He TC, Zhou S, da Costa LT, et al. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A 1998; 95:2509-2514.
68. Nilsson M, Ljungberg J, Richter J, et al. Development of an adenoviral vector system with adenovirus serotype 35 tropism; efficient transient gene transfer into primary malignant hematopoietic cells. J Gene Med 2004; 6: 631-641.
69. Mittereder N, March KL, Trapnell BC. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J Virol 1996; 70: 7498-7509.
70. Pincus S, Robertson W, Rekosh D. Characterization of the effect of aphidicolin on adenovirus DNA replication: evidence in support of a protein primer model of initiation. Nucleic Acids Res 1981; 9: 4919-4938.
71. Wildner O, Hoffmann D, Jogler C, et al. Comparison of HSV-1 thymidine kinase-dependent and -independent inhibition of replication-competent adenoviral vectors by a panel of drugs. Cancer Gene Ther 2003; 10: 791-802.
72. Contag CH, Spilman SD, Contag PR, et al. Visualizing gene expression in living mammals using a bioluminescent reporter. Photochem Photobiol 1997; 66: 523-531.
73. Bett AJ, Prevec L, Graham FL. Packaging capacity and stability of human adenovirus type 5 vectors. J Virol 1993; 67: 5911-5921.
74. Li Y, Pong RC, Bergelson JM, et al. Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy. Cancer Res 1999; 59: 325-330.
75. Douglas JT, Kim M, Surnerel LA, et al. Efficient oncolysis by a replicating adenovirus (ad) in vivo is critically dependent on tumor expression of primary ad receptors. Cancer Res 2001; 61: 813-817.
76. Hoffmann D, Heim A, Nettelbeck DM, et al. Evaluation of twenty human adenoviral types and one infectivity-enhanced adenovirus for the therapy of soft tissue sarcoma. Hum Gene Ther 2007; 18: 51-62.
77. Fueyo J, Alemany R, Gomez-Manzano C, et al. Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J Natl Cancer Inst 2003; 95: 652-660.
78. Wang W, Zhu NL, Chua J, et al. Retargeting of adenoviral vector using basic fibroblast growth factor ligand for malignant glioma gene therapy. J Neurosurg 2005; 103: 1058-1066.
79. Huang KC, Altinoz M, Wosik K, et al. Impact of the coxsackie and adenovirus receptor (CAR) on glioma cell growth and invasion: requirement for the C-terminal domain. Int J Cancer 2005; 113: 738-745.
80. Havenga MJ, Lemckert AA, Ophorst OJ, et al. Exploiting the natural diversity in adenovirus tropism for therapy and prevention of disease. J Virol 2002; 76: 4612-4620.
81. Davison E, Kirby I, Whitehouse J, et al. Adenovirus type 5 uptake by lung adenocarcinoma cells in culture correlates with Ad5 fibre binding is mediated by alpha(v)betal integrin and can be modulated by changes in betal integrin function. J Gene Med 2001; 3:550-559.
82. Shayakhmetov DM, Papayannopoulou T, Stamatoyannopoulos G, et al. Efficient gene transfer into human CD34(+) cells by a retargeted adenovirus vector. J Virol 2000; 74: 2567-2583.
83. Ishii N, Tada M, Hamou MF, et al. Cells with TP53 mutations in low grade astrocytic tumors evolve clonally to malignancy and are an unfavorable prognostic factor. Oncogene 1999; 18: 5870-5878.
84. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000; 182: 311-322.
85. Uehara K, Matsubara. S, Kadomatsu K, et al. Genomic structure of human midkine (MK), a retinoic acid-responsive growth/differentiation factor. J Biochem (Tokyo) 1992; 1ll: 563-567.
86. Duchrow M, Schluter C, Wohlenberg C, et al. Molecular characterization of the gene locus of the human cell proliferation-associated nuclear protein defined by monoclonal antibody Ki-67. Cell Prolif 1996; 29: 1-12.